Rock Springs Capital Management
Latest statistics and disclosures from Rock Springs Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BPMC, IMCR, NBIX, EVH, ISRG, and represent 19.96% of Rock Springs Capital Management's stock portfolio.
- Added to shares of these 10 stocks: LLY (+$80M), CLDX (+$37M), OSCR (+$31M), SGRY (+$29M), MDGL (+$24M), VKTX (+$21M), ACHC (+$21M), NVO (+$19M), INSP (+$19M), GPCR (+$18M).
- Started 19 new stock positions in CRL, OSCR, ELVN, CRNX, Kyverna Therapeutics, NMRA, NUVL, PHVS, JSPR, BHVN. Cg Oncology, VKTX, GPCR, AUTL, SGRY, NVO, LLY, DYN, VERA.
- Reduced shares in these 10 stocks: HUM (-$100M), Karuna Therapeutics Ord (-$86M), Seagen (-$85M), CERE (-$84M), Mirati Therapeutics (-$49M), IMCR (-$37M), Horizon Therapeutics (-$30M), Abcam Plc Ads (-$29M), AGIO (-$28M), .
- Sold out of its positions in Abcam Plc Ads, SLRN, SYRE, AMGN, BCEL, AURA, CRVO, CYTK, DSGN, FATE.
- Rock Springs Capital Management was a net seller of stock by $-198M.
- Rock Springs Capital Management has $3.9B in assets under management (AUM), dropping by 5.51%.
- Central Index Key (CIK): 0001595725
Tip: Access up to 7 years of quarterly data
Positions held by Rock Springs Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rock Springs Capital Management
Rock Springs Capital Management holds 113 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 6.0 | $237M | -6% | 2.5M | 94.86 |
|
| Immunocore Hldgs Ads (IMCR) | 3.9 | $154M | -19% | 2.4M | 65.00 |
|
| Neurocrine Biosciences (NBIX) | 3.7 | $146M | -14% | 1.1M | 137.92 |
|
| Evolent Health Cl A (EVH) | 3.3 | $131M | +3% | 4.0M | 32.79 |
|
| Intuitive Surgical Com New (ISRG) | 3.0 | $119M | 299k | 399.09 |
|
|
| UnitedHealth (UNH) | 2.9 | $114M | 230k | 494.70 |
|
|
| Penumbra (PEN) | 2.9 | $113M | 505k | 223.18 |
|
|
| IDEXX Laboratories (IDXX) | 2.5 | $97M | -7% | 179k | 539.93 |
|
| Acadia Healthcare (ACHC) | 2.4 | $93M | +29% | 1.2M | 79.22 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.3 | $90M | -11% | 229k | 393.72 |
|
| Boston Scientific Corporation (BSX) | 2.1 | $84M | +6% | 1.2M | 68.49 |
|
| Ultragenyx Pharmaceutical (RARE) | 2.1 | $83M | +20% | 1.8M | 46.69 |
|
| Dex (DXCM) | 2.1 | $83M | +2% | 597k | 138.70 |
|
| Eli Lilly & Co. (LLY) | 2.0 | $80M | NEW | 103k | 777.96 |
|
| Freshpet (FRPT) | 1.9 | $77M | 663k | 115.86 |
|
|
| Madrigal Pharmaceuticals (MDGL) | 1.9 | $76M | +45% | 286k | 267.04 |
|
| EXACT Sciences Corporation (EXAS) | 1.9 | $73M | +4% | 1.1M | 69.06 |
|
| Align Technology (ALGN) | 1.8 | $72M | 220k | 327.92 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 1.7 | $66M | -4% | 1.5M | 43.33 |
|
| Edwards Lifesciences (EW) | 1.6 | $62M | 647k | 95.56 |
|
|
| Kymera Therapeutics (KYMR) | 1.6 | $61M | 1.5M | 40.20 |
|
|
| Celldex Therapeutics Com New (CLDX) | 1.5 | $58M | +174% | 1.4M | 41.97 |
|
| Phreesia (PHR) | 1.4 | $57M | +33% | 2.4M | 23.93 |
|
| Insulet Corporation (PODD) | 1.4 | $55M | -15% | 320k | 171.40 |
|
| West Pharmaceutical Services (WST) | 1.4 | $54M | -32% | 137k | 395.71 |
|
| Xenon Pharmaceuticals (XENE) | 1.4 | $54M | +6% | 1.3M | 43.05 |
|
| Agilon Health (AGL) | 1.4 | $54M | +6% | 8.8M | 6.10 |
|
| Merus N V (MRUS) | 1.3 | $52M | +36% | 1.1M | 45.03 |
|
| Agios Pharmaceuticals (AGIO) | 1.3 | $52M | -34% | 1.8M | 29.24 |
|
| Humana (HUM) | 1.3 | $51M | -66% | 147k | 346.72 |
|
| Mirum Pharmaceuticals (MIRM) | 1.2 | $47M | 1.9M | 25.12 |
|
|
| Irhythm Technologies (IRTC) | 1.2 | $46M | +11% | 392k | 116.00 |
|
| Shockwave Med (SWAV) | 1.1 | $44M | -8% | 135k | 325.63 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.1 | $44M | -31% | 290k | 151.17 |
|
| Sarepta Therapeutics (SRPT) | 1.1 | $42M | -16% | 328k | 129.46 |
|
| Brooks Automation (AZTA) | 1.1 | $42M | +45% | 695k | 60.28 |
|
| Alnylam Pharmaceuticals Call Option (ALNY) | 1.0 | $41M | 277k | 149.45 |
|
|
| Olink Hldg Ab Sponsored Ads (OLK) | 1.0 | $39M | 1.7M | 23.51 |
|
|
| Immunovant (IMVT) | 0.9 | $37M | +78% | 1.2M | 32.31 |
|
| Accolade (ACCD) | 0.9 | $37M | +21% | 3.5M | 10.48 |
|
| Akero Therapeutics (AKRO) | 0.8 | $33M | -8% | 1.3M | 25.26 |
|
| Oscar Health Cl A (OSCR) | 0.8 | $31M | NEW | 2.1M | 14.87 |
|
| Pacira Pharmaceuticals (PCRX) | 0.8 | $31M | 1.1M | 29.22 |
|
|
| Revolution Medicines (RVMD) | 0.8 | $30M | +27% | 924k | 32.23 |
|
| Lifestance Health Group (LFST) | 0.7 | $30M | +30% | 4.8M | 6.17 |
|
| Surgery Partners (SGRY) | 0.7 | $29M | NEW | 985k | 29.83 |
|
| Warby Parker Cl A Com (WRBY) | 0.7 | $28M | +32% | 2.1M | 13.61 |
|
| Inozyme Pharma (INZY) | 0.7 | $28M | 3.7M | 7.66 |
|
|
| Inspire Med Sys (INSP) | 0.7 | $28M | +193% | 131k | 214.79 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.7 | $28M | +8% | 500k | 56.09 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.7 | $27M | +6% | 8.1M | 3.30 |
|
| Travere Therapeutics (TVTX) | 0.7 | $26M | +89% | 3.4M | 7.71 |
|
| Cerevel Therapeutics Hldng I (CERE) | 0.6 | $23M | -78% | 548k | 42.27 |
|
| Disc Medicine (IRON) | 0.6 | $23M | 364k | 62.26 |
|
|
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.6 | $22M | 562k | 38.82 |
|
|
| Viking Therapeutics (VKTX) | 0.5 | $21M | NEW | 261k | 82.00 |
|
| Dynavax Technologies Corp Com New (DVAX) | 0.5 | $21M | -7% | 1.7M | 12.41 |
|
| Zai Lab Adr (ZLAB) | 0.5 | $21M | +4% | 1.3M | 16.02 |
|
| Macrogenics (MGNX) | 0.5 | $19M | +10% | 1.3M | 14.72 |
|
| Novo-nordisk A S Adr (NVO) | 0.5 | $19M | NEW | 148k | 128.40 |
|
| Krystal Biotech (KRYS) | 0.5 | $19M | +14% | 104k | 177.93 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.5 | $18M | +37% | 3.5M | 5.08 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.4 | $18M | NEW | 413k | 42.86 |
|
| Pharvaris N V (PHVS) | 0.4 | $17M | NEW | 753k | 23.11 |
|
| Prothena Corp SHS (PRTA) | 0.4 | $16M | 625k | 24.77 |
|
|
| Nevro (NVRO) | 0.4 | $15M | -12% | 1.1M | 14.44 |
|
| Vera Therapeutics Cl A (VERA) | 0.4 | $15M | NEW | 341k | 43.12 |
|
| Mersana Therapeutics (MRSN) | 0.3 | $14M | -10% | 3.0M | 4.48 |
|
| Amicus Therapeutics (FOLD) | 0.3 | $14M | +8% | 1.2M | 11.78 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.3 | $14M | NEW | 289k | 46.81 |
|
| Charles River Laboratories (CRL) | 0.3 | $13M | NEW | 49k | 270.95 |
|
| BioMarin Pharmaceutical (BMRN) | 0.3 | $13M | -43% | 149k | 87.34 |
|
| Dyne Therapeutics (DYN) | 0.3 | $13M | NEW | 452k | 28.39 |
|
| Jasper Therapeutics Com New (JSPR) | 0.3 | $12M | NEW | 404k | 29.36 |
|
| Compass Therapeutics (CMPX) | 0.3 | $11M | 5.5M | 1.98 |
|
|
| Edap Tms S A Sponsored Adr (EDAP) | 0.3 | $11M | +8% | 1.5M | 7.35 |
|
| Mineralys Therapeutics (MLYS) | 0.3 | $10M | -32% | 793k | 12.91 |
|
| Applied Therapeutics (APLT) | 0.3 | $10M | +85% | 1.5M | 6.80 |
|
| Nuvalent Inc-a (NUVL) | 0.2 | $9.4M | NEW | 125k | 75.09 |
|
| Acumen Pharmaceuticals (ABOS) | 0.2 | $9.3M | -18% | 2.3M | 4.05 |
|
| Immatics SHS (IMTX) | 0.2 | $8.9M | -54% | 849k | 10.51 |
|
| Neumora Therapeutics (NMRA) | 0.2 | $8.9M | NEW | 646k | 13.75 |
|
| Enliven Therapeutics (ELVN) | 0.2 | $7.5M | NEW | 429k | 17.59 |
|
| Cg Oncology | 0.2 | $7.5M | NEW | 171k | 43.90 |
|
| Biohaven (BHVN) | 0.2 | $6.9M | NEW | 127k | 54.69 |
|
| Fulcrum Therapeutics (FULC) | 0.2 | $6.9M | 728k | 9.44 |
|
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $6.6M | NEW | 1.0M | 6.38 |
|
| Pulmonx Corp (LUNG) | 0.2 | $6.0M | 652k | 9.27 |
|
|
| Aurinia Pharmaceuticals (AUPH) | 0.1 | $5.8M | +139% | 1.2M | 5.01 |
|
| Essa Pharma Com New (EPIX) | 0.1 | $5.7M | 677k | 8.49 |
|
|
| Pliant Therapeutics (PLRX) | 0.1 | $5.7M | -21% | 385k | 14.90 |
|
| Beam Therapeutics (BEAM) | 0.1 | $4.9M | +32% | 148k | 33.04 |
|
| Vincerx Pharma Com New (VINC) | 0.1 | $4.5M | 892k | 5.06 |
|
|
| Kyverna Therapeutics | 0.1 | $4.4M | NEW | 179k | 24.84 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $4.2M | +4% | 771k | 5.42 |
|
| Gossamer Bio (GOSS) | 0.1 | $3.9M | 3.3M | 1.18 |
|
|
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.1 | $3.8M | 9.6M | 0.40 |
|
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $3.8M | -12% | 2.4M | 1.58 |
|
| Aclaris Therapeutics (ACRS) | 0.1 | $3.4M | -30% | 2.8M | 1.24 |
|
| Compugen Ord (CGEN) | 0.1 | $3.3M | 1.3M | 2.58 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 0.1 | $2.9M | -34% | 1.0M | 2.84 |
|
| Travere Therapeutics Note 2.500% 9/1 (Principal) | 0.1 | $2.8M | 3.3M | 0.87 |
|
|
| Biomea Fusion (BMEA) | 0.1 | $2.7M | 181k | 14.95 |
|
|
| Novavax Com New (NVAX) | 0.1 | $2.6M | -16% | 538k | 4.78 |
|
| Leap Therapeutics Com New (LPTX) | 0.1 | $2.4M | -15% | 912k | 2.66 |
|
| Spruce Biosciences (SPRB) | 0.1 | $2.1M | -4% | 2.6M | 0.79 |
|
| Neurocrine Biosciences Note 2.250% 5/1 (Principal) | 0.0 | $1.8M | 1.0M | 1.81 |
|
|
| Vigil Neuroscience (VIGL) | 0.0 | $1.6M | 472k | 3.41 |
|
|
| Xilio Therapeutics (XLO) | 0.0 | $1.6M | 1.4M | 1.08 |
|
|
| Reneo Pharmaceuticals (RPHM) | 0.0 | $1.2M | -34% | 752k | 1.66 |
|
| Nevro Corp Note 2.750% 4/0 (Principal) | 0.0 | $474k | 500k | 0.95 |
|
|
| Talphera Com New (TLPH) | 0.0 | $326k | 317k | 1.03 |
|
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $41k | 134k | 0.30 |
|
Past Filings by Rock Springs Capital Management
SEC 13F filings are viewable for Rock Springs Capital Management going back to 2013
- Rock Springs Capital Management 2024 Q1 filed May 15, 2024
- Rock Springs Capital Management 2023 Q3 filed Nov. 14, 2023
- Rock Springs Capital Management 2023 Q2 filed Aug. 14, 2023
- Rock Springs Capital Management 2023 Q1 filed May 15, 2023
- Rock Springs Capital Management 2022 Q4 filed Feb. 14, 2023
- Rock Springs Capital Management 2022 Q3 filed Nov. 14, 2022
- Rock Springs Capital Management 2022 Q2 filed Aug. 15, 2022
- Rock Springs Capital Management 2022 Q1 filed May 16, 2022
- Rock Springs Capital Management 2021 Q4 filed Feb. 14, 2022
- Rock Springs Capital Management 2021 Q3 filed Nov. 15, 2021
- Rock Springs Capital Management 2021 Q2 filed Aug. 16, 2021
- Rock Springs Capital Management 2021 Q1 filed May 17, 2021
- Rock Springs Capital Management 2020 Q4 filed Feb. 16, 2021
- Rock Springs Capital Management 2020 Q3 filed Nov. 16, 2020
- Rock Springs Capital Management 2020 Q2 filed Aug. 14, 2020
- Rock Springs Capital Management 2020 Q1 filed May 15, 2020